Adjuvant anthracycline-based chemotherapy for early breast cancer: Do the dose and schedule matter?

Cancer Treatment Reviews

Volumn 31, Issue 2, 2005, Pages 69-78

  Mano, Max S ^a   Awada, Ahmad ^b   Kerr, Janet ^a   Canney, Peter ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant therapy; Anthracyclines; Breast cancer

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TEGAFUR; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

AMENORRHEA; ARTICLE; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG RESEARCH; DRUG SENSITIVITY; DRUG USE; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; META ANALYSIS; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OPTIMAL DRUG DOSE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; TREATMENT OUTCOME;

EID: 17444395980     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.11.001     Document Type: Article

References (81)

1. Early Breast Cancer Trialists' Collaborative Group. 2000 analysis overview results. In: Fifth meeting of the Early Breast Cancer Trialists' Collaborative Group. Oxford, UK; 21-23 September, 2000
2. L. Hutchins S. Green P. Ravdin et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT0102 Proc Am Soc Clin Oncol 17 1a 1998 [abstract 2]
3. M.N. Levine V.H. Bramwell K.I. Pritchard B.D. Norris L.E. Shepherd H. Abu-Zabra et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer J Clin Oncol 16 1998 2651-2658
4. C.J. Poole H.M. Earl et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF Proc Am Soc Clin Oncol 22 2003 4 [abstract 13]
5. B. Fisher A. Brown N. Dimitrov et al. Two months of doxorubicin-cyclophosphamide with and without interval re-induction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-non-responsive tumors results: From the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1990 1483-1496
6. B. Fisher S. Anderson E. Tan-Chiu et al. Tamoxifen and chemotherapy for axillary node-negative estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 J Clin Oncol 19 4 2001 931-942
7. J.T. Carpenter E. Velez-Garcia et al. Five year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: A Southeastern Cancer Study Group Study Proc Am Soc Clin Oncol 13 1994 66
8. J.L. Misset M. di Palma M. Delgado et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration J Clin Oncol 14 4 1996 1136-1145
9. S. De Placido F. Perrone C. Carlomagno et al. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study) Br J Cancer 71 6 1995 1283-1287
10. M.E. Marty R.C. Coombs et al. Prospective meta-analysis of randomised trials of cyclophosphamide, methotrexate & fluorouracil (CMF) vs fluorouracil, epirubicin & cyclophosphamide (FEC) chemotherapy in early breast cancer Proc Am Soc Clin Oncol 2004 592 [abstract]
11. H. Mouridsen J. Andersen M. Andersson et al. Adjuvant anthracycline in breast cancer: Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin Proc Am Soc Clin Oncol 18 1999 68a
12. F. Ploner R. Jakesz H. Hausmaninger et al. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients Onkologie 26 2 2003 115-119
13. M.J. Piccart A. Di Leo M. Beauduin et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer J Clin Oncol 19 12 2001 3103-3110
14. M.J. Piccart A. Di Leo M. Beauduin et al. Ann Oncol 14 5 2003 693-698
15. A.R. Bianco R. Costanzo G. Lorenzo et al. The Mam-1 GOCSI trial: A randomised trial with factorial design of chemo-endocrine adjuvant treatment in node-positive (N+) early breast cancer (EBC) Proc Am Soc Clin Oncol 2001 104 [abstract]
16. G. Bonadonna P. Valagussa Dose-response effect of adjuvant chemotherapy in breast cancer N Engl J Med 304 1 1981 10-15
17. Paridaens R, Wildiers J, Dumez H. Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): A retrospective analysis. Ann Oncol 13(Suppl. 5):45
18. M. Colleoni K. Price M. Castiglione-Gertsch A. Goldhirsch A. Coates J. Lindtner J. Collins R.D. Gelber B. Thurlimann C.M. Rudenstam Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group Eur J Cancer 34 11 1998 1693-1700
19. The Ludwig BCSG A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Ludwig Breast Cancer Study Group Cancer Res 45 9 1985 4454-4459
20. D.W. Miles K. Ryder R.D. Rubens R.C. Leonard D.A. Cameron Comparison of three weekly (q3w) vs four weekly (q4w) adjuvant CMF chemotherapy in operable breast cancer Br Cancer Res Treat Suppl. 82 1 2003 135
21. E. Engelsman J.C. Klijn R.D. Rubens et al. Classical CMF versus a3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Cooperative Group phase III trial Eur J Cancer 27 1991 966-970
22. D.W. Rea L. Hiller H.M. Earl et al. Tolerability and efficacy of classical CMF(cCMF) using oral cyclophosphamide (OC) vs intravenous cyclophosphamide (IVC) in early stage breast cancer: A non-randomised comparison of patients (pts) treated in the National Epirubicin Adjuvant Trial (NEAT) Proc Am Soc Clin Oncol 2004 595 [abstract]
23. A.P. Launchbury N. Habboubi Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity Cancer Treat Rev 19 3 1993 197-228
24. H.T. Mouridsen C. Alfthan L. Bastholt et al. Current status of epirubicin (farmorubicin) in the treatment of solid tumours Acta Oncol 29 3 1990 257-285
25. T. Delozier J.C. Vernhes Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature Bull Cancer 78 11 1991 1013-1025 [in French]
26. M. Bontenbal M. Andersson J. Wildiers G. Cocconi J. Jassem R. Paridaens N. Rotmensz R. Sylvester H.T. Mouridsen J.G. Klijn A.T. van Oosterom Doxorubicin vs epirubicin, report of a second-line randomized phase II/ III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group Br J Cancer 77 12 1998 2257-2263
27. J.A. van der Hage C.J. van de Velde J.P. Julien M. Tubiana-Hulin C. Vandervelden L. Duchateau Preoperative chemotherapy in primary operable breast cancer results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 22 2001 4224-4237
28. B. Fisher J. Bryant N. Wolmark et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 1998 2672-2685
29. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19(3):602-11
30. D.R. Budman D.A. Berry C.T. Cirrincione et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 90 16 1998 1205-1211
31. D.A. Cameron C. Massie G. Kerr R.C. Leonard Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 10 2003 1837-1842
32. C. Mayers T. Panzarella I.F. Tannock Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer 91 12 2001 2246-2257
33. P. Poikonen T. Saarto J. Lundin H. Joensuu C. Blomqvist Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF Br J Cancer 80 11 1999 1763-1766
34. T. Saarto C. Blomqvist P. Rissanen A. Auvinen I. Elomaa Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer Br J Cancer 75 2 1997 301-305
35. J. Bergh T. Wiklund B. Erikstein et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401 Ann Oncol 9 4 1998 403-411
36. J. Bergh T. Wiklund B. Erikstein et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study Lancet 356 9239 2000 1384-1391
37. I.C. Henderson D.A. Berry G.D. Demetri et al. Improved outcomes from adding sequential Paditaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 6 2003 976-983
38. C. Bernard-Marty M. Mano M. Paesmans et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients Ann Oncol 14 5 2003 693-698
39. K.I. Pritchard M.N. Levine V.H.C. Bramwell et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer update of NCIC CTG MA5 Br Cancer Res Treat 2002 [abstract 17]
40. M. Crump D. Tu L. Shepherd M. Levine V. Bramwell K. Pritchard Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 21 16 2003 3066-3071
41. K. Albain S. Green P. Ravdin Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: New findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100) Proc Am Soc Clin Oncol 2001 94
42. C.H. Haskell S.J. Green G.W. Sledge Jr. Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A → C) in breast cancer patients with 0-3 positive nodes (intergroup 0137) Proc Am Soc Clin Oncol 2002 142
43. R.E. Smith J. Bryant A. DeCillis S. Anderson Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience J Clin Oncol 21 7 2003 1195-1204
44. P. Fumoleau P. Kerbrat P. Romestaing et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial J Clin Oncol 21 2 2003 298-305
45. S. Paik J. Bryant E. Tan-Chiu et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 J Natl Cancer Inst 92 24 2000 1991-1998
46. A. DiLeo D. Gancberg D. Larsimont et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 5 2002 1107-1116
47. A. Moliterni S. Menard P. Valagussa et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer J Clin Oncol 21 3 2003 458-462
48. P.M. Ravdin S. Green K.S. Albain et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with Tamoxifen (T) alone Proc Am Clin Soc Oncol 1998 [abstract 374]
49. S. Paik J. Bryant C. Park et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer J Natl Cancer Inst 90 18 1998 1361-1370
50. D.C. Allred G.M. Clark A.K. Tandon et al. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma J Clin Oncol 10 4 1992 599-605
51. B.A. Gusterson R.D. Gelber A. Goldhirsch et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 7 1992 1049-1056
52. D.W. Miles W.H. Harris C.E. Gillett P. Smith D.M. Barnes Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/ fluorouracil Int J Cancer 84 4 1999 354-359
53. Bianco AR, De Laurentis M, Carlomagno C, et al. Twenty-year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17:97a [abstract 373]
54. O. Stal A. Borg M. Ferno A.C. Kallstrom P. Malmstrom B. Nordenskjold South Sweden Breast Cancer Group. Southeast Sweden Breast Cancer Group.ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer Ann Oncol 11 12 2000 1545-1550
55. M.A. Climent M.A. Segui G. Peiro et al. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment Breast 10 1 2001 67-77
56. S. Menard P. Valagussa S. Pilotti et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables J Clin Oncol 19 2 2001 329-335
57. D.A. Berry H.B. Muss A.D. Thor et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer J Clin Oncol 18 20 2000 3471-3479
58. A.S. Knoop S.M. Bentzen M.M. Nielsen B.B. Rasmussen C. Rose Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients J Clin Oncol 19 14 2001 3376-3384
59. A.D. Thor D.A. Berry D.R. Budman et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer J Natl Cancer Inst 90 18 1998 1346-1360
60. Y.S. Kim S.N. Konoplev F. Montemurro et al. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation Clin Cancer Res 7 12 2001 4008-4012
61. M. Hensel A. Schneeweiss H.P. Sinn et al. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support Int J Cancer 100 3 2002 290-296
62. M. Bewick M. Conlon S. Gerard et al. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support Bone Marrow Transplant 27 8 2001 847-853
63. Y. Nieto P.J. Cagnoni S. Nawaz et al. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation J Clin Oncol 18 10 2000 2070-2080
64. J.D. Bitran B. Samuels Y. Trujillo L. Klein L. Schroeder J. Martinec Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy Clin Cancer Res 2 9 1996 1509-1513
65. G.E. Konecny C. Thomssen H.J. Luck et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer J Natl Cancer Inst 96 15 2004 1141-1151
66. A. Di Leo S. Chan M. Paesmans et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Breast Cancer Res Treat 86 3 2004 197-206
67. A.M. Gonzalez-Angulo S. Krishnamurthy Y. Yamamura et al. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma Cancer 101 2 2004 258-263
68. T.A. Jarvinen M. Tanner V. Rantanen et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer Am J Pathol 156 3 2000 839-847
69. K. Smith S. Houlbrook M. Greenall J. Carmichael A.L. Harris Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity Oncogene 8 4 1993 933-938
70. T.A. Jarvinen J. Kononen M. Pelto-Huikko J. Isola Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer Am J Pathol 148 6 1996 2073-2082
71. F. Cardoso V. Durbecq D. Larsimont et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/ metastatic breast cancer Int J Oncol 24 1 2004 201-209
72. T. Aas A.L. Borresen S. Geisler et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients Nat Med 2 7 1996 811-814
73. P.C. Clahsen C.J. van de Velde C. Duval et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer J Clin Oncol 16 2 1998 470-479
74. D. Kandioler S. Taucher B. Steiner et al. p-53 genotype and major response to anthracycline or paclitaxel based neoadjuvant chemotherapy in breast cancer patients Proc Am Soc Clin Oncol 17 1998 102a [abstract 392]
75. H.B. Muss A.D. Thor D.A. Berry et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer N Engl J Med 330 18 1994 1260-1266
76. L. Mauriac G. MacGrogan et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol 10 1 1999 47-52
77. L. Gianni J. Baselga W. Eiermann et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease Proc Am Soc Clin Oncol 2002 [abstract 132]
78. H.M. Kuerer L.A. Newman T. Smith et al. Clinical course of cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoajuvant chemotherapy J Clin Oncol 17 1999 460-469
79. Semiglazov VF, Bojok AA, Arsumanov AS, et al. Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicln vs fluorouracil + doxorubicin + cyclophosphamide in locally advanced breast cancer. Proc San Antonio Breast Cancer Symposium; 2002 [abstract 159]
80. A.U. Buzdar V. Valero et al. Pathological complete response to chemotherapy is related to hormone receptor status Breast Cancer Res Treat 82 Suppl. 1 2003 [abstract 302]
81. L. Pusztai M. Ayers F.W. Simmans et al. Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer Proc Am Soc Clin Oncol 22 2003 1 [abstract 1]